Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891290885> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2891290885 endingPage "TPS9599" @default.
- W2891290885 startingPage "TPS9599" @default.
- W2891290885 abstract "TPS9599 Background: Previous clinical trials have shown that vemurafenib significantly increases PFS and OS in untreated BRAFV600 mutant advanced melanoma patients. Nevertheless, disease progression occurs after a median of 6-7 months since start of vemurafenib. Several mechanisms of acquired resistance to vemurafenib result in reactivation of MAPK pathway. Upfront addition of a MEK inhibitor (MEKi) to vemurafenib delays secondary resistance to BRAFi. The combination of cobimetinib, a MEKi, plus vemurafenib as a continuous administration was approved by FDA in 2,015 in untreated metastatic BRAFV600 advanced melanoma patients based on an increase in PFS and OS achieved in a phase III trial (coBRIM trial). Preclinical models have shown that continuous vemurafenib dosing promotes the clonal expansion of drug-resistant cells, and intermittent dosing could serve to eliminate the fitness advantage of the resistant cells and delay the onset of drug-resistant disease (Das Thakur, Nature 2013). These observations and some clinical case reports support upfront evaluation of alternative dosing regimens of MAPK pathway inhibition. Methods: This is a randomized phase II study to explore the efficacy and safety of two schedules of administration of vemurafenib in combination with cobimetinib (continuous – 28-day cycles with vemurafenib 960 mg PO BID, Days 1-28, and cobimetinib 60 mg PO QD, Days 1-21 – and intermittent – same dose/schedule during first 12 weeks, and then, same doses with the following schedule: vemurafenib 4 weeks on /2 weeks off, and cobimetinib 3 weeks on/ 3 weeks off), in patients with untreated, BRAFV600 mutated, unresectable, measurable (RECIST 1.1), locally advanced or metastatic melanoma. Prior adjuvant immunotherapy is allowed. Primary endpoint is PFS. Secondary endpoints include: OS, ORR, pharmacokinetic and pharmacodynamic profiles and safety. Additional translational research to analyze predictive factors and mechanism of resistance will be explored. The trial is in progress; 56 of up to 116 planned pts have been recruited at the end of December 2016 (enrollment started in June 2015). Clinical trial information: NCT02583516." @default.
- W2891290885 created "2018-09-27" @default.
- W2891290885 creator A5068271097 @default.
- W2891290885 creator A5072143967 @default.
- W2891290885 creator A5080626646 @default.
- W2891290885 date "2017-05-20" @default.
- W2891290885 modified "2023-09-26" @default.
- W2891290885 title "A randomized phase II study of vemurafenib plus cobimetinib continuous versus intermittent in previously untreated BRAF V600-mutation positive patients with unresectable locally advanced or metastatic melanoma." @default.
- W2891290885 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.tps9599" @default.
- W2891290885 hasPublicationYear "2017" @default.
- W2891290885 type Work @default.
- W2891290885 sameAs 2891290885 @default.
- W2891290885 citedByCount "1" @default.
- W2891290885 countsByYear W28912908852019 @default.
- W2891290885 crossrefType "journal-article" @default.
- W2891290885 hasAuthorship W2891290885A5068271097 @default.
- W2891290885 hasAuthorship W2891290885A5072143967 @default.
- W2891290885 hasAuthorship W2891290885A5080626646 @default.
- W2891290885 hasConcept C126322002 @default.
- W2891290885 hasConcept C126894567 @default.
- W2891290885 hasConcept C143998085 @default.
- W2891290885 hasConcept C184235292 @default.
- W2891290885 hasConcept C2776131300 @default.
- W2891290885 hasConcept C2777288759 @default.
- W2891290885 hasConcept C2777658100 @default.
- W2891290885 hasConcept C2781249067 @default.
- W2891290885 hasConcept C2994587330 @default.
- W2891290885 hasConcept C31760486 @default.
- W2891290885 hasConcept C502942594 @default.
- W2891290885 hasConcept C535046627 @default.
- W2891290885 hasConcept C57074206 @default.
- W2891290885 hasConcept C71924100 @default.
- W2891290885 hasConcept C86803240 @default.
- W2891290885 hasConcept C95444343 @default.
- W2891290885 hasConcept C98274493 @default.
- W2891290885 hasConceptScore W2891290885C126322002 @default.
- W2891290885 hasConceptScore W2891290885C126894567 @default.
- W2891290885 hasConceptScore W2891290885C143998085 @default.
- W2891290885 hasConceptScore W2891290885C184235292 @default.
- W2891290885 hasConceptScore W2891290885C2776131300 @default.
- W2891290885 hasConceptScore W2891290885C2777288759 @default.
- W2891290885 hasConceptScore W2891290885C2777658100 @default.
- W2891290885 hasConceptScore W2891290885C2781249067 @default.
- W2891290885 hasConceptScore W2891290885C2994587330 @default.
- W2891290885 hasConceptScore W2891290885C31760486 @default.
- W2891290885 hasConceptScore W2891290885C502942594 @default.
- W2891290885 hasConceptScore W2891290885C535046627 @default.
- W2891290885 hasConceptScore W2891290885C57074206 @default.
- W2891290885 hasConceptScore W2891290885C71924100 @default.
- W2891290885 hasConceptScore W2891290885C86803240 @default.
- W2891290885 hasConceptScore W2891290885C95444343 @default.
- W2891290885 hasConceptScore W2891290885C98274493 @default.
- W2891290885 hasIssue "15_suppl" @default.
- W2891290885 hasLocation W28912908851 @default.
- W2891290885 hasOpenAccess W2891290885 @default.
- W2891290885 hasPrimaryLocation W28912908851 @default.
- W2891290885 hasRelatedWork W1435076864 @default.
- W2891290885 hasRelatedWork W1975512933 @default.
- W2891290885 hasRelatedWork W2023835753 @default.
- W2891290885 hasRelatedWork W2328771497 @default.
- W2891290885 hasRelatedWork W2468709891 @default.
- W2891290885 hasRelatedWork W2481729799 @default.
- W2891290885 hasRelatedWork W2885961494 @default.
- W2891290885 hasRelatedWork W3045209127 @default.
- W2891290885 hasRelatedWork W3131108980 @default.
- W2891290885 hasRelatedWork W3200436128 @default.
- W2891290885 hasVolume "35" @default.
- W2891290885 isParatext "false" @default.
- W2891290885 isRetracted "false" @default.
- W2891290885 magId "2891290885" @default.
- W2891290885 workType "article" @default.